| 13.26 Data as of 3:59pm ET |  +0.18 / +1.38%Today’s Change | 10.05 Today|||52-Week Range 17.09 | +12.47% Year-to-Date |
| Previous close | 13.08 |
| Today’s open | 13.22 |
| Day’s range | 13.14 - 13.60 |
| Volume | 365,560 |
| Average volume (3 months) | 306,448 |
| Market cap | $679.2M |
| Dividend yield | -- |
| Earnings growth (last year) | -132.68% |
| Earnings growth (this year) | -61.81% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -77.42% |
| P/E ratio | NM |
| Price/Sales | 9.30 |
| Price/Book | 1.88 |
| Today’s change | Today’s % change | |
|---|---|---|
| SZYMSolazyme Inc | -0.72 | -6.24% |
| ITMNInterMune Inc | -0.40 | -4.00% |
| HALOHalozyme Therapeutic... | -0.42 | -5.53% |
| PLXProtalix Biotherapeu... | 0.00 | 0.00% |
| Next reporting date | August 6, 2013 |
| EPS forecast (this quarter) | -$0.46 |
| Annual revenue (last year) | $63.9M |
| Annual profit (last year) | -$58.6M |
| Net profit margin | -91.75% |
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Craig A. Wheeler, MBA |
Chief Financial Officer & Senior Vice President Richard P. Shea, MBA, CPA |
Corporate headquarters Cambridge, Massachusetts |
.
